clean quarter improv time
holog result appear compani first clean quarter last
month compani still work achiev desir mid-singl
digit growth aspir believ share reflect encourag
underli trend appear improv breast health sale
post ex-fx growth best quarter year demonstr new
product intern servic leverag share gain growth diagnost
sale post ex-fx growth molecular growth highlight
growth gyn surgic sale hit mark overal flat growth outlook
seem brighter novasur given compani recent legal victori patent
infring case minerva final cynosur sale improv q/q
think continu improv salesforc execut offer opportun
attract medic aesthet market environ surpris learn
cfo bob mcmahon resign join agil compani new cfo
retir agil cfo didier hirsch though time appear good given
clean quarter agil cfo opportun look attract ow pt
also clearli see lot valu creation opportun well newli promot
cfo karleen oberton decad experi
plan analysi excit meet soon think promot
bring stabil role financ team
look sept fye moder ep forecast
emb addit conservat
model ahead
manag initi guidanc forecast overal growth ex-fx includ
breast health/skelet growth diagnost growth gyn surgic growth
cynosur growth forecast ebit margin expans
driven opex lever busi model free cash flow gener remain
signific lever capit deploy repurchas alreadi complet drive
tailwind ep think valuat still screen attract
ebitda price-to-earnings reiter overweight rate
quarterli annual ep usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
overweight believ grow
stronger longer driven longer
mammographi tail mdx growth panther
myosur tuck-in new product launch
could drive modest upsid revenu
mdx gyn surgic busi continu
drive outsiz growth new product launch
add modestli growth upsid case
reflect upsid earn power
penetr rate us mammographi
busi slow faster expect downsid
case reflect downsid earn
power
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
holog result appear compani first clean quarter last
month compani still work achiev desir mid-singl digit
growth aspir believ share reflect encourag
underli trend appear improv breast health sale post ex-fx
growth best quarter year demonstr new product intern
servic leverag share gain growth diagnost sale post ex-
fx growth molecular growth highlight growth gyn surgic
sale hit mark overal flat growth outlook seem brighter novasur given
compani recent legal victori patent infring case minerva final
cynosur sale improv q/q think continu improv
salesforc execut offer opportun attract medic aesthet market
environ surpris learn cfo bob mcmahon resign join
agil compani new cfo retir agil cfo didier hirsch
though time good given clean quarter agil cfo opportun
look attract ow pt also clearli see lot valu creation opportun
well newli promot cfo karleen oberton decad experi
compani cao sinc lead global financ
controllership function financi plan analysi excit meet soon
think promot bring stabil role financ team
look sept fye moder ep forecast
emb addit conservat model ahead manag
initi guidanc year forecast overal growth constant currenc
includ breast health/skelet growth diagnost growth gyn surgic
growth cynosur growth forecast ebit margin expans
driven opex lever busi model free cash flow gener remain signific
lever capit deploy repurchas alreadi complet drive tailwind
ep think valuat still screen attract ebitda
price-to-earnings reiter overweight rate
underli driver holog guidanc appear unchang
cleaner quarter revenu anticip rang billion
million midpoint previou guidanc repres report growth
constant currenc growth low-singl digit organ growth
estim midpoint addit estim three fewer sell day
headwind top line revenu forecast rang
million repres declin growth embed
guidanc fx headwind lead constant currenc growth
account headwind blood screen divestitur one-
time royalti estim organ growth rang
adjust benefit addit sell day estim
underli organ growth rang segment basi gyn surgic
expect return growth cynosur grow y/i though declin
given summer season diagnost face tougher comp million royalti
payment
tighten ep guidanc anticip rang
consist previou guidanc midpoint impli growth
guidanc emb advers fx environ previous
expect compani expect non-gaap tax rate year well
dilut share count million previou forecast million
adjust ep expect rang
revenu increas y/i million organ revenu grew y/i
sequenti quarter growth follow chang manag late
compani post anoth strong quarter intern growth ex-fx
exclud blood screen cynosur total intern revenu increas y/i
strength led breast health constant currenc gyn
surgic constant currenc encourag strength
compani molecular diagnost busi driven strength panther
placement compani women health aptima assay manag
previous note viral load revenu remain small compani encourag
growth seen intern
revenu organ growth
look segment saw healthi result breast return
growth gyn surgic perform diagnost cynosur weaker
expect
diagnost revenu segment revenu grew y/i ex-fx molecular
diagnost increas y/i ex-fx driven increas market share util
panther system notabl intern diagnost grew y/i organ
driven women health offer compani full menu sexual
health viral load respiratori assay market global total estim
nearli panther place diagnost custom includ
unit state remind compani complet sale blood screen
busi januari cytolog perinat revenu decreas ex-fx
million
breast revenu revenu grew y/i ex-fx despit increas
market penetr geniu mammographi placement remain strong
quarter help eas concern potenti mammographi cliff
addit strong servic revenu million quarter driven
larger instal base intervent breast solut anoth strong quarter
growth y/i ex-fx new product affirm brevera improv
breast revenu y/i coupl anoth strong quarter
intern revenu y/i ex-fx estim compani us
placement quarter estim bring cumul placement
cynosur rev revenu declin y/i ex-fx sale declin y/i
tough comp q/q typic softer follow call
manag reset expect busi compani believ
result repres step right direct compani believ
cynosur eventu growth engin model
cynosur revenu million sequenti
gyn surgic revenu increas y/i ex-fx million
manag continu see strong perform myosur post
ex-fx growth novasur weaken post declin ex-fx though
manag encourag stabil two disappoint quarter
revenu segment
declin friday juli announc district court
district delawar award million damag minerva surgic
infring two patent relat endometri ablat technolog
court also reject minerva defens infring seek
injunct prohibit minerva manufactur sell infring
devic unit state think appeal rule like posit
rule could bolster competit posit push market-lead
novasur product custom
skelet health revenu increas y/i ex-fx segment specif
saw growth dxa product servic manag note quarterli sale
expect improv cours year driven better portfolio sell
increas interest horizon bone densitometri system bodi composit
test new mini c-arm product
breast health deliv organ growth driven combin resili us
placement servic growth new product intern share gain
improv convict segment grow low-to-mid singl digit
compani approach penetr instal base compani
conserv tone around placement opportun compani exhaust
leav smaller
commun hospit custom gener price sensit order size
smaller make placement opportun harder come manag roll
addit tier product help penetr smaller site unlik
cycl believ help extend tail placement eas
concern potenti mammographi cliff
multi-ord placement opportun
specif breast imag compani report million revenu
y/i ex-fx driven strength intern us breast health busi improv
y/i howev intern busi grew y/i ex-fx along
stronger sale system growth driven servic new product revenu
compani focus number new product introduct includ
perform system also recent launch brevera
expect system contribut growth quarter addit compani
note amid competit environ gain market share
put growth perspect chart note estim placement
end total estim penetr amongst
exist custom base stabl sequenti trend placement consist
fda mqsa data publish describ placement rate larg
steadi mammographi upgrad cycl drive growth servic revenu due
higher price contract
also announc acquisit faxitron bioptic roughli million
expand breadth compani breast health portfolio faxitron
privat compani product rang digit specimen radiographi sentinel
lymph node biopsi solut product sold distribut channel call
cfo bob mcmahon note faxitron gener million revenu last
fiscal year believ improv faxitron gross margin
current compani averag faxitron meaning impact
financi acquisit expect neutral ep
accret thereaft nearli faxitron employe join
remind saw acceler ffdm placement rate earli
acceler driven factor
includ reimburs
mammographi addit renew invest sale market ge
siemen back launch new unit keep mind calendar fourth
quarter year typic season weak given time rsna
confer loss sell week
unit placement unit barclay holog inc
quarterli placement ffdm unit
monthli placement ffdm unit
made signific progress de-lever follow cynosur
acquisit reach point capit deploy repres real
opportun compani exit quarter net debt/ebitda ratio
expect declin end follow portfolio chang
compani leverag remain point pursu addit capit
deploy believ compani priorit tuck-in acquisit absent
would expect compani pay debt repurchas share believ gyn
surgic diagnost like area could augment
placementstot unitsdigit unitsquarterli unit barclay holog inc
net debt ttm ebitda
breast health leverag compani commerci breadth drive new
product growth suit pleas see announc
million acquisit faxitron bioptic leader digit specimen radiographi
think good exampl tuck-in acquisit make sens fit
gyn surgic could also attract area tuck-in addit product
 ad product gyn surgic portfolio would better leverag gyn
sale forc third product market ob/gyn
diagnost point care poc notabl gap compani portfolio
critiqu poc market mani compani
success gener profit said point care one
fastest grow area coverag sustain secular tailwind relat
consumer healthcar would natur cross-sel opportun
hospit touch point panther mdx system
non-gaap ep increas y/i forecast
debt ebitda barclay holog inc
non-gaap ep growth number vari penni quarterli number
page round issu
gross margin declin y/i driven primarili geograph
mix intern sale carri lower gross margin addit gross margin
impact lower-margin cynosur product sale gross margin expect
flat slightli improv rest year cynosur consum mix
increas percentag revenu help margin time
gross margin annual improv
oper margin declin y/i due impact
geograph mix gross margin rel compani averag divest
blood screen busi higher margin cynosur margin dilut given
acquir asset commerci infrastructur oper expens continu
pressur oper margin go forward sale market ex-comp
came revenu q/q expens revenu ex-
comp q/q ex-comp revenu declin y/i
adjust ex-comp sg trend
product revssg rev barclay holog inc
 mm except ep reportedincom profit ebitda ebit pre-tax pre-tax tax net adj net researchprior yearprior quarter barclay inc
estestestestestestestestestincom statement y/i q/q y/i q/q y/i growth y/i growth y/i ex-fx organ ex-sel q/q product sale product product revenu inc servic gross gross margin inc y/i sale y/i stock comp sg y/i ebitda y/i oper incom ebit y/i invest expens outstand incom pre-tax y/i benefit incom tax net incom adj net y/i averag number share dilut y/i net barclay holog inc
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
